Category: Peptides Research

Every now and then, a compound stops me mid-chart review and demands my full attention. PT-141 was one of those moments — and I wasn’t even looking for it. I was consulting on a spinal cord injury case, examining whether supraspinal pathways might still mediate certain physiological responses when peripheral nerve signaling is disrupted. The…

Read more

Halfway through a twelve-hour craniotomy a few years back, I found myself thinking about something that had nothing to do with the surgical field in front of me. I was thinking about what, exactly, was keeping this patient’s brain alive. Not the anesthesia, not the monitors — the underlying cellular machinery. The mitochondria cycling through…

Read more

I was skeptical when a colleague first slid a paper on Semax across the conference table. A synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, developed in the Soviet Union in the 1980s, with a clinical history primarily documented in Russian-language literature — that’s not the kind of origin story that commands instant credibility…

Read more

There’s a peptide circulating in your bloodstream right now that peaks in your 20s and falls by roughly 60% by the time you reach 60. When I first came across that statistic in a pharmacology review, I stopped and re-read it twice. I’d spent years focused on neurological repair, growth factors, and cellular signaling —…

Read more

The first time a colleague handed me a paper on SS-31 peptide, I almost set it aside. A mitochondria-targeting tetrapeptide felt like fringe science — not the hard clinical data I’d built my career on. Then I read the mechanism. A compound that specifically partitions into the inner mitochondrial membrane, binds cardiolipin, and reduces oxidative…

Read more

I’ve sat across from patients who checked out fine on every scan we ran — no lesion, no bleed, no structural abnormality — and yet they couldn’t sleep, couldn’t focus, and lived in a low-grade state of dread they couldn’t quite name. That clinical gap haunts me. It’s part of why, a few years into…

Read more

Late one evening, I was reviewing post-stroke recovery literature — the kind of deep dive that starts at 11 PM and somehow becomes 2 AM. Most of what I read was familiar territory: standard neurological endpoints, predictable outcome measures. Then a study from the Institute of Molecular Genetics in Moscow stopped me cold. Researchers were…

Read more

Three amino acids. That’s it — lysine, proline, valine, strung together in a sequence so short you’d be forgiven for dismissing it as chemically insignificant. The first time I encountered KPV peptide research in the literature, I almost did exactly that. Then I read what this tripeptide does to NF-κB signaling in inflamed gut tissue,…

Read more

The human body already makes its own broad-spectrum antimicrobial compound. After years in neurosurgery — managing post-operative infections, watching the immune system either hold the line or fold under pressure — that fact still strikes me as remarkable. We pour billions into external antibiotics each year, yet one of the most powerful defense molecules was…

Read more